[Mitomycin C in head and neck surgical procedures].
Mitomycin C (MMC) is frequently used in combination chemotherapy. Its metabolites bind to DNA-molecules and causes DNA crosslinking, which interferes with the synthesis of DNA, RNA and proteins. MMC is thus able to reduce fibroblast proliferation. Moreover, MMC particularly inhibits the synthesis of extracellular matrix proteins including fibronectin and various collagens. These properties have been demonstrated in several experimental studies. Beside its merits in treatment of malignancies, MMC may thus be useful to prevent hypertrophic scars and keloids, adhesions and ostial restenosis following head and neck surgical procedures. Clinically, MMC has been applied to prevent scarring after ophthalmologic surgery. Recent experimental and clinical trials investigating the effects of MMC on wound healing following head and neck surgical procedures are reviewed.
Scheithauer
M O
MO
HNO-Universitätsklinik und Poliklinik Ulm. marc.scheithauer@uniklinikulm.de
Riechelmann
H
H
D000477:Alkylating Agents / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D002921:Cicatrix / Q000517:prevention & control; D004247:DNA / Q000187:drug effects; D005347:Fibroblasts / Q000187:drug effects; D005500:Follow-Up Studies; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D010038:Otorhinolaryngologic Diseases / Q000601:surgery*; D010256:Paranasal Sinuses / Q000601:surgery; D011446:Prospective Studies; D012313:RNA / Q000187:drug effects; D011817:Rabbits; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D000267:Tissue Adhesions / Q000517:prevention & control; D014945:Wound Healing / Q000187:drug effects*
D000477:Alkylating Agents; D016685:Mitomycin; D012313:RNA; D004247:DNA